Paratek Pharma Shares Rise 3% Pre-Bell as Study Shows ‘Potent’ Activity of Omadacycline vs Pathogens

Paratek Pharmaceuticals (PRTK) shares gained more than 3% in pre-market trade Friday after the company said a study showed that its once-daily, oral and IV, broad-spectrum investigational antibiotic, omadacycline is active against the clinically important typical and atypical community-acquired bacterial pneumonia pathogens.

The data show in vitro antibacterial activity and clinical efficacy against gram-positive and gram-negative bacterial isolates, Paratek said.

Separately, Paratek said that three sub-analyses from a phase 3 study show a consistent safety and efficacy profile of omadacycline when treating acute bacterial skin and skin structure infections in patients with comorbid conditions, which could be associated with reduced treatment efficacy and increased safety-related adverse events.